Evidence map›Paper›PMID 36114256›Full record

ArticleScientific reports2022

A machine learning COVID-19 mass screening based on symptoms and a simple olfactory test.

Youcef Azeli, Alberto Fernández, Federico Capriles, Wojciech Rojewski, Vanesa Lopez-Madrid, David Sabaté-Lissner, Rosa Maria Serrano, Cristina Rey-Reñones, Marta Civit, Josefina Casellas and 4 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Youcef AzeliServei d'Urgències, Hospital Universitari Sant Joan, Reus, Spain. youcefazeli@gencat.cat.
Alberto FernándezDepartament d'Enginyeria Química, Universitat Rovira i Virgili, Tarragona, Spain.
Federico CaprilesServei d'Urgències, Hospital Universitari Sant Joan, Reus, Spain.
Wojciech RojewskiServei d'Urgències, Hospital Universitari Sant Joan, Reus, Spain.
Vanesa Lopez-MadridServei d'Urgències, Hospital Universitari Sant Joan, Reus, Spain.
David Sabaté-LissnerCUAP Reus, Gerència Territorial Camp de Tarragona, Institut Català de la Salut, Tarragona, Spain.
Rosa Maria SerranoServei d'Urgències, Hospital Universitari Sant Joan, Reus, Spain.
Cristina Rey-ReñonesResearch Support Unit-Camp de Tarragona, Catalan Institute of Health (ICS), Tarragona, Spain.
Marta CivitCUAP Reus, Gerència Territorial Camp de Tarragona, Institut Català de la Salut, Tarragona, Spain.
Josefina CasellasServei d'Urgències, Hospital Universitari Sant Joan, Reus, Spain.
Abdelghani El Ouahabi-El OuahabiServei d'Urgències, Hospital Universitari Sant Joan, Reus, Spain.
Maria Foglia-FernándezORL Service Sant Joan University Hospital, Reus, Spain.
Salvador SarráDirecció Médica, Hospital Universitari Sant Joan, Reus, Spain.
Eduard LlobetMINOS-IURESCAT, Universitat Rovira i Virgili, Tarragona, Spain.
Hospital Universitari Sant Joan de Reus · ESInstitut Català de la Salut · ESUniversidad Rovira i Virgili · ESConsorci d’Atenció Primària de Salut Barcelona Esquerra · ESInstitut Universitari d'Investigació en Atenció Primària Jordi Gol · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The early detection of symptoms and rapid testing are the basis of an efficient screening strategy to control COVID-19 transmission. The olfactory dysfunction is one of the most prevalent symptom and in many cases is the first symptom. This study aims to develop a machine learning COVID-19 predictive tool based on symptoms and a simple olfactory test, which consists of identifying the smell of an aromatized hydroalcoholic gel. A multi-centre population-based prospective study was carried out in the city of Reus (Catalonia, Spain). The study included consecutive patients undergoing a reverse transcriptase polymerase chain reaction test for presenting symptoms suggestive of COVID-19 or for being close contacts of a confirmed COVID-19 case. A total of 519 patients were included, 386 (74.4%) had at least one symptom and 133 (25.6%) were asymptomatic. A classification tree model including sex, age, relevant symptoms and the olfactory test results obtained a sensitivity of 0.97 (95% CI 0.91-0.99), a specificity of 0.39 (95% CI 0.34-0.44) and an AUC of 0.87 (95% CI 0.83-0.92). This shows that this machine learning predictive model is a promising mass screening for COVID-19.

Indexed as

COVID-19SmellHumansMachine LearningMass ScreeningProspective Studies

Identifiers

PMID36114256
PMCPMC9481525
OpenAlexW4296070692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.